ストックスクリーナーアプリを入手
44.80
0.24%
-0.11
Travere Therapeutics Inc (TVTX) 最新ニュース
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes - BioSpace
Director plans sale of 2,181 shares after RSU vesting (NASDAQ: TVTX) - Stock Titan
Insider sells shares; TVTX (NASDAQ: TVTX) files Form 144 reporting RSU vesting - Stock Titan
Jula Inrig sells 20,000 shares (NASDAQ: TVTX) — Form 144 filing - Stock Titan
Insider sale filing — TVTX (NASDAQ: TVTX) Peter Heerma sold 7,215 shares - Stock Titan
Travere Therapeutics plans $400 million convertible notes offering - Investing.com
Roy Baynes files sale of 4,500 shares (NASDAQ: TVTX) under Rule 144 - Stock Titan
Travere Therapeutics plans $400 million convertible notes offering By Investing.com - Investing.com Australia
Travere Therapeutics plans $400M convertible notes offering - MSN
Travere Therapeutics (NASDAQ: TVTX) seeks $400M convertible notes - Stock Titan
Travere lines up $400M debt sale, aims to repurchase 2029 notes - Stock Titan
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings - Benzinga
MSN Money - MSN
3 Stocks Estimated To Be Trading Up To 49.9% Below Intrinsic Value - simplywall.st
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2026 Earnings Call Transcript - Insider Monkey
Travere Therapeutics price target raised to $57 from $47 at H.C. Wainwright - TipRanks
Travere Therapeutics, Inc. Q1 2026: Financial Results, Risk Factors, and Management Discussion - Minichart
Travere Therapeutics Reports First Quarter 2026 Financial Results - BioSpace
Travere Therapeutics Inc SEC Filings - Stock Titan
How (TVTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Why Travere Therapeutics (TVTX) Is Up 10.0% After Stronger Q1 2026 Results And Narrower Loss - simplywall.st
Travere Therapeutics Bets Big on FILSPARI Momentum - TipRanks
Travere Therapeutics : Investor Fact Sheet - marketscreener.com
Travere Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Travere Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
TVTX: FILSPARI's FDA approval in FSGS fueled record Q1 sales and positions for rapid future growth - TradingView
Travere Therapeutics (TVTX) reports Q1 loss, misses revenue estimates - MSN
TVTX: Record Filspari sales and first FSGS approval drive strong growth and outlook - TradingView
Travere (TVTX) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Travere Q1 2026 sees mixed results, stock rises - Investing.com Australia
Travere Therapeutics reports Q1 EPS 5c, consensus (5c) - TipRanks
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance Singapore
Travere Therapeutics Q1 Swings to Profit, Revenue Rises - marketscreener.com
Travere Therapeutics : Q1 2026 Earnings Presentation - marketscreener.com
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Travere therapeutics director Roy Baynes sells $431,145 in stock. By Investing.com - Investing.com Canada
Travere Therapeutics (NASDAQ: TVTX) grows FILSPARI sales as FDA fully approves FSGS use - Stock Titan
Travere therapeutics director Roy Baynes sells $431,145 in stock. - Investing.com
Travere Therapeutics 1Q 2026: Revenue $127.2M, EPS ($0.4) — 10-Q Summary - TradingView
TVTX: FILSPARI sales drove 56% revenue growth and improved net loss, with strong liquidity maintained - TradingView
Travere Therapeutics falls on revenue miss despite record demand By Investing.com - Investing.com Australia
Travere Therapeutics falls on revenue miss despite record demand - Investing.com
Q1 2026 Travere Therapeutics Inc Earnings Call Transcript - GuruFocus
Earnings Flash (TVTX) Travere Therapeutics, Inc. Posts Q1 Adjusted EPS $0.05 per Share - marketscreener.com
Travere Therapeutics (TVTX) director sells 9,750 shares via 10b5-1 plan - Stock Titan
Earnings Flash (TVTX) Travere Therapeutics, Inc. Reports Q1 Revenue $127.2M, vs. FactSet Est of $136.2M - marketscreener.com
Travere: Q1 Earnings Snapshot - wwltv.com
FILSPARI growth lifts Travere (NASDAQ: TVTX) to Q1 2026 non-GAAP profit - Stock Titan
20,000-share sale notice for Morgan Stanley Smith Barney (TVTX) via option exercise - Stock Titan
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
TVTX (NASDAQ) files Rule 144 for 20,000-share option exercise; prior April sales listed - Stock Titan
Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Travere Therapeutics faces earnings test after FSGS approval By Investing.com - Investing.com Australia
Travere Therapeutics faces earnings test after FSGS approval - Investing.com
Travere Therapeutics (TVTX) Is Up 8.9% After Stronger Quarter And Insider Sales Activity – Has The Bull Case Changed? - Yahoo Finance
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):